Image For Activity Cover
2022 SAT6 Pushing Back Against HCM: Can Cardiac Myosin Inhibitors Alter the Disease Progression & Management Trajectory for Patients With Hypertrophic Cardiomyopathy?
Pushing Back Against HCM: Can Cardiac Myosin Inhibitors Alter the Disease Progression and Management Trajectory for Patients With Hypertrophic Cardiomyopathy?
Activity Description
How are you pushing back against HCM in your practice? In PeerView’s latest CME/MOC/NCPD/CPE-certified activity, a panel of experts will present a MasterClass and Practicum on integrating cardiac myosin inhibitors into clinical practice. Learn how to apply the latest guidelines and sharpen your diagnostic skills to identify patients with HCM while hearing the latest recommendations for the individualized management of patients with obstructive HCM, including team-based collaboration. This activity also looks to the future and reviews the latest evidence for using cardiac myosin inhibitors in nonobstructive disease.


Educational Objectives
Upon completion of this activity, participants should be better able to:
  1. Identify the mechanism of action of cardiac myosin inhibitors in the treatment of patients with HCM Apply the latest recommendations and evidence-based guidance to diagnose and manage patients with HCM in a collaborative, team-based manner
  2. Describe the efficacy and safety of cardiac myosin inhibitors, including the ability to reduce eligibility for septal reduction therapy, to address unmet needs among patients with obstructive and non-obstructive HCM.
  3. Collaborate with patients and clinical colleagues to better identify patients with HCM and achieve their personal goals and desired outcomes pertaining to HCM management.

Target Audience
This activity has been designed to meet the educational needs of heart failure specialists, cardiovascular surgeons, general cardiologists, internal medicine physicians, family physicians, advanced practice clinicians (NPs/PAs), nurses, pharmacists, and other healthcare professionals involved in the management of HCM.

Credits Offered:
  • 1.0 MOC credit
  • 1.0 pharmacy credit
  • 1.0 contact hour (NCPD, Nursing)
  • 1.0 CME

NOTE:  Please submit your date of birth in MM/DD/YY format if you are claiming MOC or CPE (Pharmacy) credits.  Please submit your 6 digit ABIM number if you are claiming MOC.  Please submit your NAPB ID number if you are claiming pharmacy credits.  If you need to look up your ABIM number, go to abim.org/verify-physician

Please claim your credit on the Peerview Platform.

See more at Pushing Back Against HCM: Can Cardiac Myosin Inhibitors Alter the Diease Progression and Management Trajectory for Patients with Hypertrophic Cardiomyopathy?
Summary
Cost: $0.00
Credit:
No Credit Offered
Recommended
Powered by Oasis.